Condition

HR+/HER2- Breast Cancer clinical trials and research

• 14Clinical trials
• 2NIH research projects
• 1New in 30 days
• 19Countries

Newest HR+/HER2- Breast Cancer clinical trials

All recruiting trials (14)

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• AI-powered pre-treatment MRI to predict chemotherapy response in HR+/HER2- breast cancer

  This study tests whether AI analysis of baseline DCE-MRI can forecast which HR+/HER2- breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting at 5 sites Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07702708

• Dalpiciclib plus hormone therapy for early HR+/HER2- breast cancer

  This trial tests whether adding dalpiciclib at two different doses and durations to standard hormone therapy helps people with early HR+/HER2- breast cancer.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian and 1 other locations · NCT07581834

• BGB-43395 plus letrozole vs standard CDK4/6 inhibitor with letrozole for advanced HR+/HER2- breast cancer

  A phase 3 trial tests whether adding BGB-43395 to letrozole works better than the usual CDK4/6 inhibitor plus letrozole in adults with advanced or metastatic HR+/HER2- breast cancer who have not yet received treatment for advanced disease.

  Recruiting at 241 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 240 other locations · NCT07492641

• Marker-guided adjuvant elacestrant versus standard endocrine therapy for intermediate-to-high-risk HR+/HER2- early breast cancer

  This trial will test whether giving elacestrant (with or without a CDK4/6 inhibitor) as initial adjuvant therapy for adults with gene-test or clinical intermediate-to-high-risk HR+/HER2- early breast cancer reduces recurrence compared with standard endocrine treatment.

  Recruiting at 28 sites Phase 3 Women's Cancer Study Group GmbH · Mannheim, Baden-Wurttemberg and 32 other locations · NCT07242352

• Personalized chemo decisions for young HR+/HER2- breast cancer patients

  This trial tests whether using a genomic test can safely spare some premenopausal patients from chemotherapy in favor of endocrine therapy alone.

  Recruiting at 23 sites Phase 3 Unicancer · Brussels and 104 other locations · NCT07106632

• AVZO-023 alone or with AVZO-021 and hormone therapy for advanced HR+/HER2- breast cancer

  This will test whether the oral drug AVZO-023, given alone or with AVZO-021 and hormone therapy, is safe and can help control advanced HR+/HER2- breast cancer.

  Recruiting at 16 sites Phase 1/2 Avenzo Therapeutics, Inc. · Los Angeles, California and 15 other locations · NCT06998407

• Neoadjuvant chemotherapy with Toripalimab for HR+/HER2- breast cancer

  This study is testing if adding a new immunotherapy drug called Toripalimab to standard chemotherapy can help people with HR+/HER2- breast cancer respond better to treatment.

  Recruiting at 2 sites Phase 3 First Affiliated Hospital of Zhejiang University · Hangzhou and 12 other locations · NCT06977893

• Neoadjuvant QL1706 plus chemotherapy for early HR-positive/HER2-negative breast cancer

  This trial tests whether adding QL1706 to pre-surgery chemotherapy improves the chance of a complete tumor response in people with early HR+/HER2- breast cancer.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou · NCT06967103

• Pre-surgery chemotherapy with anlotinib and benmelstobart for HR+/HER2- breast cancer

  This trial tests whether adding anlotinib and benmelstobart to pre-surgery chemotherapy helps people with hormone receptor–positive, HER2‑negative breast cancer achieve a complete response before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 2 other locations · NCT06874933

• Serplulimab plus nab-paclitaxel and epirubicin for early HR+/HER2- breast cancer

  This Phase 2 study will test whether adding serplulimab to nab-paclitaxel and epirubicin before surgery helps shrink early-stage HR+/HER2- breast cancers in adults.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06860529

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Neoadjuvant chemotherapy with Toripalimab for HR+/HER2- breast cancer

  This study is testing if adding Toripalimab to standard chemotherapy can help women with HR+/HER2- breast cancer respond better to treatment before surgery.

  Recruiting at 3 sites Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou and 10 other locations · NCT06611813

• Treatment of advanced solid tumors with AVZO-021

  This study is testing a new oral medication called AVZO-021 to see if it can safely help people with advanced solid tumors, especially certain types of breast cancer and other cancers with specific genetic changes.

  Recruiting at 13 sites Phase 1/2 Avenzo Therapeutics, Inc. · New Haven, Connecticut and 12 other locations · NCT05867251

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• BRD8's role in hormone-receptor positive, HER2-positive breast cancer

  This project looks at whether targeting a protein called BRD8 can help people with hormone-receptor positive, HER2-positive breast cancer respond better to HER2 treatments.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11284108

• Understanding how BRD8 affects hormone receptor-positive and HER2-positive breast cancer

  This study is looking into how a protein called BRD8 affects breast cancer that is both hormone receptor-positive and HER2-positive, to find out why some patients don’t respond well to current treatments and to discover new ways to help them feel better.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11095727

Related topics

Quick answers

How many HR+/HER2- Breast Cancer clinical trials are recruiting right now?

14, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 19 countries. The most sites are in China (8 trials), United States (4 trials), Italy (3 trials), Australia (2 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 3: 4, Phase 1/2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →